KMO inhibitor

Cancer research
#Acute inflammatory conditions #Clinical trial #KMO inhibitor #Kynos Therapeutics #Phase I trial #University of Edinburgh

Positive Phase I results for KMO inhibitor in inflammatory disorders

Kynos Therapeutics has announced positive top line results from the first in human Phase I trial of its lead drug candidate, KMO inhibitor KNS366, for acute and chronic inflammatory disorders. KMO is an enzyme that acts at a key point in the kynurenine pathway of… Read More

#News